Current/ Expected Orderbook/ Pending Orders?

Specific current or expected order book or pending orders details were not explicitly stated in the transcript. Management highlighted ongoing growth with projects like Atali (expected completion H2 FY25) aimed at capacity expansion. Focus is on increasing tonnage and backward integration to meet demand and maintain margins. The CMO/CDMO segment is expected to grow significantly, possibly increasing from 6% to 15% contribution over the next three years. The company is actively commercializing new products each year, aiming to file around 40 DMFs per year, with 40 filed to date as of FY23. Inve

Any current/future capex/capital investment/strategic investment?

Growth capex of over INR 200 crores incurred in the last couple of years, with INR 130 crores capitalized on the Tarapur project. Ramp-up expected over next 1 to 1.5 years. Atali, Gujarat Greenfield project: 80 acres acquired; first phase involves 400k reactor volume capacity, targeting API, intermediates, and CDMO/CMO projects. Completion expected in H2 FY25. Additional capacity expansions include debottlenecking Xanthine plant from 4,000 to 5,000 tons per annum, with further debottlenecking planned. Maintenance and EHS capex typically INR 50-60 crores per year. Future capex plans include pot

Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. The company has indicated ongoing and upcoming capex projects (e.g., Atali project with INR350-500 crores capex) being funded through existing resources and internal accruals. Management highlighted reasonable debt levels and focus on EBITDA and PAT growth but did not specify raising new funds. The discussions revolve around optimizing existing capacities, backward integration, and capex funded from internal cash flows. No direct references to equity issuance or fresh borro

Future growth expectations in sales/revenue/volumes?

Company expects revenue growth of 12%-17% over the next few years, reflecting a solid but moderated pace compared to past CAGR of ~18%-20% (Page 12). Growth driven by expansion in three segments: Xanthine, API/intermediates, and CDMO/CMO businesses, with the latter poised for faster growth and higher margins (Pages 11-12). CDMO/CMO segment anticipated to grow from ~6% contribution currently to potentially 15%+ in 3 years (Page 11). Capacity expansions, including debottlenecking and new Atali project (completed by H2 FY25), will enable volume growth and new product commercializations (Pag

Future growth expectations in earnings/operating earnings/profits/EPS?

Management expects EBITDA growth in FY24 to be around 10%-15%, with sustainable EBITDA margins near 20% ±2%. Long-term top-line growth guidance is 12%-17% annually, with PAT growth potentially higher due to manageable debt levels. The CDMO/CMO segment is anticipated to grow and contribute over 10% to overall business in FY24, driving margin improvement. Capacity expansions, including de-bottlenecking xanthine production and the Atali Greenfield project (completion expected H2 FY25), support growth. Revenue growth may moderate due to price corrections in segments like Xanthine, but abso

Aarti Pharmalabs LtdQ1 FY24Pharmaceuticals & Biotechnology

Aarti Pharmalabs Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹927.65P/E: 39.0Market Cap: ₹8.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Company expects revenue growth of 12%-17% over the next few years, reflecting a solid but moderated pace compared to past CAGR of ~18%-20% (Page 12).
Growth driven by expansion in three segments: Xanthine, API/intermediates, and CDMO/CMO businesses, with the latter poised for faster growth and higher margins (Pages 11-12).
CDMO/CMO segment anticipated to grow from ~6% contribution currently to potentially 15%+ in 3 years (Page 11).
Capacity expansions, including debottlenecking and new Atali project (completed by H2 FY25), will enable volume growth and new product commercializations (Pages 6, 11).
Despite pressure on Xanthine prices, volume increase and capacity expansion aim to maintain or improve absolute EBITDA (Pages 6, 10).
New product launches, about 40 developments annually, support sales growth alongside broadening customer base in innovator pharma and food/cosmetics (Pages 3, 13).

Margin guidance

Category 3

Management expects EBITDA growth in FY24 to be around 10%-15%, with sustainable EBITDA margins near 20% ±2%.
Long-term top-line growth guidance is 12%-17% annually, with PAT growth potentially higher due to manageable debt levels.
The CDMO/CMO segment is anticipated to grow and contribute over 10% to overall business in FY24, driving margin improvement.
Capacity expansions, including de-bottlenecking xanthine production and the Atali Greenfield project (completion expected H2 FY25), support growth.
Revenue growth may moderate due to price corrections in segments like Xanthine, but absolute EBITDA and profits are expected to improve through volume increases and operational efficiencies.
R&D expenditure remains stable, fueling product filings and innovation, which should contribute to longer-term earnings growth.

See what Aarti Pharmalabs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
The company has indicated ongoing and upcoming capex projects (e.g., Atali project with INR350-500 crores capex) being funded through existing resources and internal accruals.
Management highlighted reasonable debt levels and focus on EBITDA and PAT growth but did not specify raising new funds.
The discussions revolve around optimizing existing capacities, backward integration, and capex funded from internal cash flows.
No direct references to equity issuance or fresh borrowings for expansion were made during the Q&A or management commentary sections.

Order book

Specific current or expected order book or pending orders details were not explicitly stated in the transcript.
Management highlighted ongoing growth with projects like Atali (expected completion H2 FY25) aimed at capacity expansion.
Focus is on increasing tonnage and backward integration to meet demand and maintain margins.
The CMO/CDMO segment is expected to grow significantly, possibly increasing from 6% to 15% contribution over the next three years.
The company is actively commercializing new products each year, aiming to file around 40 DMFs per year, with 40 filed to date as of FY23.
Inventories have increased but management expects these to be sold in upcoming quarters, indicating active order fulfillment underway.
Overall, the company expects stable or growing EBITDA and is optimistic about future order growth tied to capacity expansion and product pipeline.

See what Aarti Pharmalabs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Growth capex of over INR 200 crores incurred in the last couple of years, with INR 130 crores capitalized on the Tarapur project. Ramp-up expected over next 1 to 1.5 years.
Atali, Gujarat Greenfield project: 80 acres acquired; first phase involves 400k reactor volume capacity, targeting API, intermediates, and CDMO/CMO projects. Completion expected in H2 FY25.
Additional capacity expansions include debottlenecking Xanthine plant from 4,000 to 5,000 tons per annum, with further debottlenecking planned.
Maintenance and EHS capex typically INR 50-60 crores per year.
Future capex plans include potential for 2-3 additional blocks at current API sites based on demand, with flexibility to scale as utilization improves.
Capital employed for backward integration to reduce imports and improve margins, especially to reduce dependence on China.

Track Aarti Pharmalabs Ltd — get its next earnings analysis in your feed

How does Aarti Pharmalabs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAarti Pharmalabs Ltd

Rev 3Mar 3

See where Aarti Pharmalabs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Aarti Pharmalabs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Aarti Pharmalabs Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Aarti Pharmalabs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Aarti Pharmalabs Ltd Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Aarti Pharmalabs Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Aarti Pharmalabs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season